Use of rapamycin derivatives in chronic rejection

Abstract

The present invention is directed to the use of a rapamycin derivative of formula I in combination with cyclosporin for preventing or treating manifestations of chronic rejection in a recipient of an organ or tissue transplant.

1 - 10 . (canceled) 
     
     
         11 . A method for treating chronic rejection or preventing manifestations of chronic rejection in a recipient of an organ or tissue transplant, said method comprising co-administrating to said recipient an effective amount of 40-O-(2-hydroxymethyl)-rapamycin and cyclosporin A. 
     
     
         12 . The method of  claim 11  wherein the 40-O-(2-hydroxymethyl)-rapamycin and cyclosporin A are administered concomitantly. 
     
     
         13 . The method of  claim 11  wherein the 40-O-(2-hydroxymethyl)-rapamycin and cyclosporin A are administered in sequence. 
     
     
         14 . The method of  claim 11  wherein the 40-O-(2-hydroxymethyl)-rapamycin is administered in a dosage range of from about 0.25 to 25 mg. 
     
     
         15 . The method of  claim 14  wherein the dosage is administered in a single dose. 
     
     
         16 . The method of  claim 14  wherein the dosage is administered in divided doses.